Juliana Frosch, NP
Psychiatric/Mental Health · Amherst, VANPI 1578541272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,050 of the $36,218 with a category attached, or 77.4%. AbbVie accounts for 85.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $12,280 and has fallen 64.3% since, to $4,384 in 2025. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $127.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$801
- Otsuka America Pharmaceutical, Inc.$794
- Neurocrine Biosciences, Inc.$382
- Alkermes, Inc.$330
- plus $1K from 8 others
What the payments were for
- Speaking & faculty fees$28,05077%
- Travel & lodging$2,1556%
- Food & beverage$5,96716%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $31,017 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,587 |
| Johnson & Johnson | 24 | $801 |
| Otsuka America Pharmaceutical, Inc. | 47 | $794 |
| Neurocrine Biosciences, Inc. | 13 | $382 |
| Alkermes, Inc. | 19 | $330 |
| Teva Pharmaceuticals USA, Inc. | 6 | $322 |
| Axsome Therapeutics, Inc. | 9 | $248 |
| Indivior Inc. | 8 | $203 |
| E.r. Squibb & Sons, L.L.C. | 5 | $195 |
| Vanda Pharmaceuticals Inc. | 7 | $146 |
| Lundbeck LLC | 5 | $101 |
| Avanir Pharmaceuticals, Inc. | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$29,771
- CAPLYTA$832
- UZEDY$214
- SPRAVATO$131
- INGREZZA$122
- COBENFY$121
- INVEGA SUSTENNA$121
- INVEGA TRINZA$121
- Auvelity$114
How this compares
$36,218 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $222,928 |
| VraylarCariprazine Hcl | 114 | $158,592 |
| Invega TrinzaPaliperidone Palmitate | 13 | $95,810 |
| Invega SustennaPaliperidone Palmitate | 27 | $84,280 |
| RexultiBrexpiprazole | 41 | $66,531 |
| Abilify MaintenaAripiprazole | 15 | $40,464 |
| FanaptIloperidone | 12 | $25,938 |
| AuvelityDextromethorphan Hbr/Bupropion | 35 | $25,202 |
| Lurasidone Hcl | 52 | $20,708 |
| VyvanseLisdexamfetamine Dimesylate | 30 | $11,267 |
| BelsomraSuvorexant | 16 | $6,910 |
| Fluphenazine Hcl | 16 | $3,671 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $3,238 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 151 | $2,729 |
| Buspirone Hcl | 241 | $2,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $382 | $222,92826 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $801 | $180,09140 claims |
| AbbVieVraylar | $31,017 | $158,592114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $794 | $106,99556 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $146 | $25,93812 claims |
| Axsome Therapeutics, Inc.Auvelity | $248 | $25,20235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Amherst
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
- Lisa Clement DefalcoEarlysville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.